Truveta advances security and privacy with Type 2 SOC 2 examination BELLEVUE, Wash., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Truveta today announced it has completed a Type 2 System and Organization Controls (SOC) 2 examination, which underscores Truveta’s commitments to...

Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials BELLEVUE and SEATTLE, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial...

New SDOH data in Truveta Studio provide most complete view of health equity’s influence on patient health and outcomes BELLEVUE, Wash., March 01, 2023 (GLOBE NEWSWIRE) -- Truveta announced the expansion of its de-identified data to include 28 additional social drivers of health (SDOH) attributes – such as education,...

Truveta Research shares new insights on RSV hospitalization trends BELLEVUE, Wash., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Today, Truveta released new research comparing the rates of RSV to previous years. With the rising rates of respiratory syncytial virus (RSV)...

Truveta welcomes four new health system members joining its vision of saving lives with data BELLEVUE, Wash., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Four leading healthcare providers -- WellSpan Health, Centura Health, MetroHealth, and Virtua Health -- have joined Truveta, the company with a...